NCT00214994已完成3 期
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16 mg/Day) in Adults With Generalized Anxiety Disorder.
Cephalon178 个研究点 分布在 1 个国家开始时间: 2005年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 178
研究概览
简要总结
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have completed 10 weeks of double-blind treatment and the subsequent taper period in 1 of the 3 previous double-blind studies (studies C6671/3030/AX/US, C6671/3031/AX/US, or C6671/3032/AX/US).
排除标准
- 未提供
研究者
研究点 (178)
Loading locations...
相似试验
终止
2 期
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationKidney TransplantationNCT06365437ITB-Med LLC33
已完成
2 期
A Dose Escalation Study in de Novo Renal TransplantationKidney TransplantationNCT04311632ITB-Med LLC13
已完成
1 期
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis PatientsMultiple SclerosisNCT00616733Daiichi Sankyo25
已完成
1 期
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)NCT05364424Hoffmann-La Roche43
终止
1 期
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive CancersHER2 Expressing Solid TumoursNCT02829372Ichnos Sciences SA36